Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

Hayato Kawachi,Motohiro Tamiya,Yoshihiko Taniguchi,Toshihide Yokoyama,Shinya Yokoe,Yuko Oya,Mihoko Imaji,Fukuko Okabe,Masaki Kanazu,Yoshihiko Sakata,Shinya Uematsu,Satoshi Tanaka,Daisuke Arai,Go Saito,Hiroshi Kobe,Eisaku Miyauchi,Asuka Okada,Satoshi Hara,Toru Kumagai

JTO Clinical and Research Reports（2022）

引用 5|浏览14

暂无评分

摘要

ICI/Chemo seemed more effective than pembrolizumab monotherapy for patients with non-Sq NSCLC with MPE. Nevertheless, the synergistic effect of BEV with ICI/Chemo may be limited. Further studies are needed to clarify the key factor in the tumor-induced immunosuppression environment in these patients.

查看译文

关键词

Immune checkpoint inhibitor,Combination therapy,Non–small cell lung cancer,Malignant pleural effusion,Treatment outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要